Bacterial endocarditis treated with intramuscular teicoplanin.

Area of Science:

• Infectious Diseases
• Cardiology
• Pharmacology

Background:

• Parenteral drug abuse is a significant risk factor for right-sided endocarditis, often caused by Staphylococcus aureus.
• Standard treatment involves prolonged intravenous antibiotics, typically cloxacillin and aminoglycosides, or vancomycin for specific cases.
• Teicoplanin, a glycopeptide antibiotic, has shown limited success when administered intravenously for this condition.

Observation:

• A case study of a 37-year-old parenteral drug user with right-sided endocarditis is presented.
• The patient required treatment with teicoplanin due to a lack of alternative therapeutic options.
• Intravenous administration was not feasible, necessitating intramuscular delivery of teicoplanin.

Findings:

• Intramuscular administration of teicoplanin was successfully employed in this patient with right-sided endocarditis.
• This route of administration was chosen due to the absence of other viable treatment alternatives.
• The outcome suggests intramuscular teicoplanin may be a viable option in select, challenging cases.

Implications:

• This case highlights the potential utility of intramuscular teicoplanin for right-sided endocarditis when intravenous therapy is not possible.
• It expands treatment considerations for Staphylococcus aureus endocarditis in parenteral drug users.
• Further research into the efficacy and safety of intramuscular glycopeptide administration in endocarditis is warranted.